Concord-Carlisle High School students designed and built hydraulic robotic arms, showcasing their engineering skills.
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...
CSL’s fireman tells us how he’s reviving the Australian market’s Bambi. Investors are yet to reward him for it. One of the surprising things about CSL’s earnings season shocker was that it reaffirmed ...
CSL chief financial officer Ken Lim says the global healthcare giant is trying to simplify its organisation after conceding that a slowdown in its ability to make quick decisions had hurt its ...
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...
After teasing a plasma-based manufacturing expansion in the U.S. late last year, CSL is putting in the work and firming up details behind the $1.5 billion project. Monday, the Australian biopharma ...
C SL has broken ground for an expansion of its state-of-the-art manufacturing facility in Kankakee, Illinois. The newly expanded facility will substantially increase the global biopharma company’s ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Melbourne-based company will ...
Eli Lilly has been scouting for drugs to follow the trail blazed by its blockbuster cardiometabolic medicines. Its latest pipeline-building deal has the pharmaceutical company paying $100 million for ...
CSL granted Eli Lilly certain rights for clazakizumab CSl to receive upfront payment of $100 million CSL shares up 2.1% CSL will retain exclusive rights to develop and commercialise clazakizumab for ...
Feb 18 (Reuters) - Australia's CSL said on Wednesday it had entered into an exclusive licensing agreement with Eli Lilly and Co, granting it certain rights to develop and commercialise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results